Alibaba Debuts Cloud Computer, Delivery Robots at Cloud Computing Conference
17.9.2020 05:44:00 EEST | Business Wire | Press release
Alibaba Cloud, the digital technologies and intelligence backbone of Alibaba Group, today unveiled a series of innovative products at its 12th annual Apsara Conference, highlighting the technology pioneer’s commitment in helping people adapt to the more digitized world and accelerate customers’ digital transformation during and after the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916006004/en/
Alibaba Debuts First Cloud Computer (Photo: Business Wire)
A highlight is Alibaba Cloud’s first cloud computer, a palm-sized personal computer which, despite being just about 60 grams and as light as an egg, offers high-performance computing, thanks to robust back-end cloud resources. By simply connecting the cloud computer with a normal computer screen, a user can access almost unlimited computing resources anytime, anywhere, while paying on a subscription model or for the actual cloud consumption.
“We hope our cloud computer can help people access resilient computing power whenever they need to, so they can conduct complex tasks which usually require sophisticated and powerful PCs, such as video editing, animation rendering, software development, and online customer services, with a tiny personal computer at hand now,” said Jeff Zhang, President of Alibaba Cloud Intelligence. “As working from home becomes the new normal during and after the pandemic, we believe our innovation can also help users more easily enjoy the benefits of cloud computing anytime, anywhere, in a cost-effective yet secure way.”
With robust computing power, the cloud computer can reduce the rendering time of one frame high-resolution animation from 90 minutes using a traditional PC, down to only 10 minutes. In addition, the cloud computer’s system upgrades are conducted online, saving a big chunk of the normally heavy cost of PC machine upgrades and maintenance in traditional office settings. Through Alibaba Cloud's self-developed app-streaming protocol, which is designed for synergy between the cloud and the device, users can also purchase and access licensed apps and programs such Linux and Windows as well as various office applications. All user data will be stored on cloud for datacenter-grade security and protection measures. Available initially for enterprise customers, the cloud computers will be also available for purchase by individual consumers in the near future.
Alibaba Cloud also unveiled its autonomous logistics robot for last-mile deliveries. Developed by the Alibaba DAMO Academy, the global research initiative by Alibaba Group, the delivery robot can carry 50 packages at one time and cover 62 miles (or 100 kilometres) on a single charge. It is estimated the mobile robot should be able to deliver as many as 500 packages a day to one designated community or campus, meeting the rising demand for speedy last-mile delivery in China. Online shopping is booming there, with 200 million packages delivered daily and expectations that will rise to 1 billion packages per day in the coming years.
“We are expecting a rapid spike of delivery demands brought by the thriving New Retail and local services businesses in the increasingly digitalized world,” added Zhang. “To meet the strong delivery demand for our internal business growth and for the larger society, we have been investing in smart logistics, including logistics robots, for years. We are glad to launch our latest mobile delivery robot, which will support Cainiao, Alibaba’s logistics platform, to serve communities, campuses and business parks in China. “
“Moving ahead, we aim to support the delivery needs of our local services businesses and leverage our technologies for other types of service robots, such as service robots in the airport and tourism guide robots in scenic spots.”
Supported with reinforced learning technologies, the intelligent robot can schedule its route even in a crowded environment. With proprietary, high-definition positioning technology, the robot can operate even where there’s weak or no GPS signal. Leveraging a self-developed heterogeneous computing platform, 3D Point Cloud Semantic Segmentation (PCSS) technology and deep learning, the robot can also identify obstacles and predict the intended movement of passengers and vehicles a few seconds ahead of time to enhance safety.
Consumers can use either the Cainiao or Taobao mobile apps to select a preferred timeslot during the day for delivery. The robot then arrives at the designated destination, where users retrieve their packages simply by entering a passcode they receive in the app, once the robot arrives.
A slew of cloud-native products were unveiled during the Conference:
- Cloud Lakehouse: This is the next-generation big data architecture which can deliver significant data-based values and intelligence through cross-platform computing, intelligent cache, hot/cold data separation, storage improvement and performance acceleration.
- Sandboxed-Container 2.0: Alibaba’s cloud-native container service for Kubernetes supports clusters that provide sandboxed container runtimes. The new Sandboxed-Container 2.0 enables customers to run applications in lightweight sandboxed environments with faster speeds and reduced cost of runtime resources.
- PAI-DSW 2.0: The latest Cloud-native Machine-learning Interactive Development Platform by Alibaba. It aims to provide an optimal environment for developers that is easy to use, compatible with community plug-ins and supports multi-development environments like JupyterLab, WebIDE and Terminal.
- Lindorm: The cloud-native multi-model database that is used to support the Alibaba Group ecosystem, is introduced to benefit the wider Alibaba Cloud ecosystem. Lindorm is a cloud-native database, with affordable storage and flexible processing characteristics. It is designed for applications with massive processing requirements for a mixture of unstructured, semi-structured, and structured data.
The conference, named “Leap Into the Future of Digital Intelligence,” was entirely hosted online for the first time, with over 100 virtual forums on topics ranging from cloud computing, IoT to machine learning and industrial AI solutions.
For more information about the Apsara Conference, please visit the website: https://www.alibabacloud.com/apsara-conference-2020
About Alibaba Cloud
Established in 2009, Alibaba Cloud (alibabacloud.com), the digital technology and intelligence backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner. It is also the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and public services. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916006004/en/
Contact information
Media Contact:
Crystal Liu
Crystal.liu@alibaba-inc.com
+86 18578497650
Luica Mak
luica.mak@alibaba-inc.com
+44-7905471332
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
